# A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of Twice Daily Topical Applications of AP611074 5% Gel for up to 16 Weeks in Condyloma Patients

> **NCT02724254** · PHASE2 · COMPLETED · sponsor: **Vaxart** · enrollment: 218 (actual)

## Conditions studied

- Condyloma

## Interventions

- **DRUG:** AP611074 5% gel
- **DRUG:** AP611074 matching placebo

## Key facts

- **NCT ID:** NCT02724254
- **Lead sponsor:** Vaxart
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-01
- **Primary completion:** 2018-05
- **Final completion:** 2018-07
- **Target enrollment:** 218 (ACTUAL)
- **Last updated:** 2018-07-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02724254

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02724254, "A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of Twice Daily Topical Applications of AP611074 5% Gel for up to 16 Weeks in Condyloma Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02724254. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*